Unituxin — Total revenues
United Therapeutics Unituxin — Total revenues decreased by 14.0% to $53.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.9%, from $58.20M to $53.60M. Over 4 years (FY 2021 to FY 2025), Unituxin — Total revenues shows an upward trend with a 2.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market share or higher demand for the product, while a decrease may signal market saturation, competition, or product lifecycle maturity.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeut...
Peer comparison
Commonly reported as 'Product Revenue' or 'Segment Revenue' in pharmaceutical financial disclosures.
uthr_segment_unituxin_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $53.10M | $55.30M | $50.00M | $55.60M | $44.50M | $46.10M | $36.70M | $49.10M | $44.30M | $51.30M | $54.20M | $58.40M | $51.70M | $61.10M | $67.50M | $58.20M | $58.40M | $47.90M | $62.30M | $53.60M |
| QoQ Change | — | +4.1% | -9.6% | +11.2% | -20.0% | +3.6% | -20.4% | +33.8% | -9.8% | +15.8% | +5.7% | +7.7% | -11.5% | +18.2% | +10.5% | -13.8% | +0.3% | -18.0% | +30.1% | -14.0% |
| YoY Change | — | — | — | — | -16.2% | -16.6% | -26.6% | -11.7% | -0.4% | +11.3% | +47.7% | +18.9% | +16.7% | +19.1% | +24.5% | -0.3% | +13.0% | -21.6% | -7.7% | -7.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's unituxin — total revenues?
- United Therapeutics (UTHR) reported unituxin — total revenues of $53.60M in Q1 2026.
- How has United Therapeutics's unituxin — total revenues changed year-over-year?
- United Therapeutics's unituxin — total revenues decreased by 7.9% year-over-year, from $58.20M to $53.60M.
- What is the long-term trend for United Therapeutics's unituxin — total revenues?
- Over 4 years (2021 to 2025), United Therapeutics's unituxin — total revenues has grown at a 2.9% compound annual growth rate (CAGR), from $202.30M to $226.80M.
- What does unituxin — total revenues mean?
- The total sales revenue generated by a specific product line.